Jasper Therapeutics, Inc. (JSPR) |
|
0.65 -0.027 (-3.99%)
|
09-27 10:20 |
|
Open: |
0.6712 |
Pre. Close: |
0.677 |
|
High:
|
0.6712 |
Low:
|
0.6498 |
|
Volume:
|
125,893 |
Market Cap:
|
72(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 9:47:23 AM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.31  One year: 1.67 |
| Support: |
Support1: 0.62 Support2: 0.51 |
| Resistance: |
Resistance1: 1.12 Resistance2: 1.42 |
| Pivot: |
0.77 |
| Moving Average: |
MA(5): 0.71 MA(20): 0.86
MA(100): 1.35 MA(250): 1.3 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 10.7 %D(3): 13.8 |
| RSI: |
RSI(14): 22.1 |
| 52-week: |
High: 3.79 Low: 0.38 |
| Average Vol(K): |
3-Month: 288 (K) 10-Days: 737 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JSPR ] has closed above bottom band by 9.9%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.75 - 0.76 |
0.76 - 0.76 |
|
Low:
|
0.61 - 0.62 |
0.62 - 0.62 |
|
Close:
|
0.67 - 0.68 |
0.68 - 0.68 |
|
Company Description |
|
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California. |
Headline News |
Mon, 25 Sep 2023
Jasper Therapeutics Appoints Herb Cross As New CFO - Nasdaq
Mon, 25 Sep 2023
Jasper Therapeutics Strengthens Leadership Team with ... - Best Stocks
Mon, 25 Sep 2023
Jasper Therapeutics (JSPR) Appoints Herb Cross as CFO - StreetInsider.com
Thu, 21 Sep 2023
Powerbridge Technologies Expands Global Trade Digital Platform ... - Best Stocks
Thu, 21 Sep 2023
Jasper Therapeutics to Present New Positive Data on Briquilimab ... - GlobeNewswire
Fri, 15 Sep 2023
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
111 (M) |
| Shares Float |
57 (M) |
|
% Held by Insiders
|
7.9 (%) |
|
% Held by Institutions
|
87.6 (%) |
|
Shares Short
|
1,090 (K) |
|
Shares Short P.Month
|
1,010 (K) |
Stock Financials |
|
EPS
|
-0.95 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-37.5 |
|
Return on Equity (ttm)
|
-65.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.52 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-46 (M) |
|
Levered Free Cash Flow
|
-29 (M) |
Stock Valuations |
|
PE Ratio
|
-0.7 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.66 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.6 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
